New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:50 EDTABBVAbbVie raises FY14 adjusted EPS to $3.06-3.16 from $3.00-$3.10, consensus $3.14
The company is raising its outlook, reflecting strong underlying business performance year to date and the expected continued positive trends over the remainder of the year, including the second quarter.
News For ABBV From The Last 14 Days
Check below for free stories on ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
07:57 EDTABBVGilead HCV risks overblown, says Bernstein
Bernstein believes that investors are concerned about upcoming competition to Gilead's (GILD) HCV drug from AbbVie's (ABBV) HCV treatment. But Bernstein says that insurers can only prevent 16% of the U.S. population from receiving Gilead's drug, and the firm does not expect the HCV market share dynamics to change in the near-term. It keeps an Outperform rating on Gilead.
August 8, 2014
07:48 EDTABBVCredit Suisse remains a buyer of AbbVie
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use